AbbVie (ABBV) Enters $3.8B Accelerated Stock Buyback Agreement

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. SPCX
2. HUM
3. ALHC
4. T
5. PEP
6. AXP
7. TMUS
8. SPY
9. CVS
10. UNH

Go back to AbbVie (ABBV) Enters $3.8B Accelerated Stock Buyback Agreement

AbbVie (ABBV) Issues Positive Update on Rova-T as r/r SCLC Treatment

June 6, 2016 6:26 AM EDT

AbbVie (NYSE: ABBV) announced that treatment with rovalpituzumab tesirine (Rova-T), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC), demonstrated a confirmed overall response rate (ORR) of 39 percent and clinical benefit rate (stable disease or better) of 89 percent in patients with recurrent or refractory small cell lung cancer (SCLC), identified with high expression of DLL3. Rova-T demonstrated a one-year overall survival (OS) rate of 32 percent in the recurrent/refractory second- and third-line patient population. These new data were presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in... More